Form 4: CalciMedica Insider Buys Shares

CalciMedica Chief Medical Officer Sudarshan Hebbar acquired 124,486 shares of common stock.

Summary

• Sudarshan Hebbar, Chief Medical Officer of CalciMedica, Inc., acquired 124,486 shares of common stock on June 25, 2026.
• The acquisition was made through a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026.
• The transaction was approved by an independent committee of the Issuer's Board of Directors.
• Following this transaction, Mr. Hebbar beneficially owns 186,025 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing due to the insider purchase, which often signals confidence, but the lack of broader financial context limits the overall positive sentiment.

Positives

• Insider purchase of a significant number of shares by a key executive (Chief Medical Officer).
• The transaction was approved by an independent committee of the Board of Directors, suggesting good corporate governance.
• The purchase price of $0.8033 per share indicates a potentially undervalued stock or a belief in future growth by the executive.

Negatives

• The filing does not provide details on the financial health or performance of CalciMedica, Inc., making it difficult to assess the broader implications of this transaction.

Risks

• The filing does not contain information on specific risks related to the company's operations or the transaction itself.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that insider purchases, especially by senior management, can signal confidence in the company's future prospects. However, without further context on CalciMedica's financial performance or strategic initiatives, the significance of this particular transaction remains limited.

Corporate Governance

Related Party Transactions

• The transaction involves Sudarshan Hebbar, Chief Medical Officer, purchasing securities directly from the Issuer (CalciMedica, Inc.).

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive signal of confidence in the company's future, potentially supporting share price. Employees: May be encouraged by executive commitment. Creditors: No direct impact indicated.

Next Steps

• Monitor future filings for further transactions by insiders or company performance updates.

Key Dates

Keywords

CalciMedica, CALC, Form 4, Insider Trading, Securities Purchase Agreement, Common Stock, Beneficial Ownership, Sudarshan Hebbar, Chief Medical Officer